FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Mochington	D C	20E 40
Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
- 1											
	OMB Number:	3235-0287									
	Estimated average burden										
- 1	ha	٥٦									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Calder Douglas W			2. Issuer Name and Ticker or Trading Symbol ZEVRA THERAPEUTICS, INC. [ZVRA]] (Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/03/2023								give title		Other (sp below)	
C/O ZEVRA THERAPEUTICS, INC. 1180 CELEBRATION BOULEVARD, SUITE 103			103	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) CELEBRATION FL 34747					Form filed by More than One Reporting Person							ing				
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						to					
		Tak	ole I - Non-	Deriva	tive	Securitie	s Ac	quired, D	isposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Execution Date,		3. Transaction Code (Instr. 3) S) S) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		ed (A) or str. 3, 4 and	Beneficia Owned F	es For ially (D) Following (I) (Form:	Direct of Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
					Code	V Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, T ecurity or Exercise (Month/Day/Year) if any C		Co	ansaction Derivative ode (Instr. Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative (Instr. 3 and		of s g e Security	Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
Co					ode \	V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (right to buy)	\$4.97 ⁽¹⁾	05/03/2023		1	A	58,800 ⁽	2)	(3)	05/02/2033	Common Stock	58,800	\$0	58,800)	D	

Explanation of Responses:

- 1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023.
- 2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.
- 3.333% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer.

/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Douglas

05/11/2023

W. Calder

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.